Patients are encouraged to consult with their healthcare provider if symptoms persist or worsen
The peptide does not bind to a known receptor with high specificity, which complicates mechanistic classification
39.9% with placebo), with nausea, vomiting, and diarrhea peaking during dose escalation and declining thereafter, whereas constipation remained relatively constant
Product quality verification remains essential for safety
The tripeptide is sensitive to oxidation upon reconstitution, particularly in neutral or alkaline solutions, so researchers should prepare fresh working solutions or add stabilizers for extended use
The FDA's own scientists had already reviewed all of this data, and recommended against it because of a lack of evidence: "Accordingly, we propose not adding BPC-157 (free base) or BPC-157 acetate to the 503A Bulks List" [12]